Toxicity associated to radiotherapy treatment in lung cancer patients

Clinical and Translational Oncology

Volumn 9, Issue 8, 2007, Pages 506-512

  Lopez Rodriguez M ^a   Cerezo Padellano, L ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Dosimetric parameters; Fibrosis; Lung toxicity; Pneumonitis

Indexed keywords

AMIFOSTINE; PREDNISOLONE; WR 27121;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CIGARETTE SMOKING; DOSE RESPONSE; DOSIMETRY; DRUG DOSE REDUCTION; HUMAN; LUNG CANCER; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG VOLUME; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION PNEUMONIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; LUNG; LUNG TUMOR; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOTHERAPY;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; LUNG; LUNG NEOPLASMS; RADIATION INJURIES; RADIATION PNEUMONITIS; RADIOTHERAPY; RISK FACTORS;

EID: 38449092213     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0094-4     Document Type: Review

References (42)

1. Rodrigues G, Lock M, D'souza D et al (2004) Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer-a systematic review. Radiother Oncol 71:127-138
2. Kong FM, Haken RT, Eisbruch A et al (2005) Non-small-cell lung cancer therapy-related pulmonary toxicity: An update on radiation pneumonitis and fibrosis. Semin Oncol 32[Suppl 3]:S42-54
3. Tsoutsou P, Koukorakis M (2006) Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys 66:1281-1293
4. Marks L, Yu X, Vujaskovic Z et al (2003) Radiationinduced lung injury. Semin Radiat Oncol 13:333-345
5. Wall RJ, Schnapp LM (2006) Radiation pneumonitis. Respir Care 51:1255-1260
6. Mehta V (2005) Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63:5-24
7. De Jaeger K, Seppenwoolde Y, Boersma LJ et al (2003) Pulmonary function following high dose radiotherapy of NSCLC. Int J Radiat Oncol Biol Phys 55:1331-1340
8. Hope A, Lindsay P, El Naqa I et al (2006) Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys 65:112-124
9. Byhardt RW, Scott C, Sause WT et al (1998) Response, toxicity, failure patterns, and survival in five RTOG trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 42:469-478
10. Roach M, Gandara DR, You HS et al (1995) Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors. J Clin Oncol 13:2606-2612
11. Senan S, De Ruysscher D, Giraud PH et al (2004) Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 71:139-146
12. Gaspar LE, Mc Coy J, Kelly K et al (2006) Analysis of V20 and Radiation Pneumonitis on SWOG0023: A phase III Trial of Concurrent Chemoradiation and Docetaxel Consolidation in Stage III Nonsmall Cell Lung Cancer. Int J Radiat Oncol Biol Phys 66[suppl 3]:S61-62
13. Oetzel D, Schraube P, Hensely F et al (1995) Estimations of pneumonitis risk in 3D treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 33:455-460
14. Armstrong J, Raben A, Zelefsky M et al (1997) Promising survival with three dimensional conformal radiation therapy for non small cell lung cancer. Radiother Oncol 44:17-22
15. Kwa SLS, Theuws JCM, Wagenaar A et al (1998) Evaluation of two dose-volume histogram reduction models for the prediction of radiation pneumonitis. Radiother Oncol 48:61-69
16. Graham M, Purdy J, Emami B et al (1999) Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for NSCLC. Int J Radiat Oncol Biol Phys 45:323-329
17. Hernando M, Marks L, Bentel G et al (2001) Radiation induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51:650-659
18. Yorke ED, Jackson A, Rosenzweig KE et al (2002) Dose-volume factors contributing to the incidence of radiation pneumonitis in non small cell lung cancer patients treated with 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys 54:329-339
19. Tsujino K, Hirota S, Endo M et al (2003) Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 55:110-115
20. Claude L, Pérol D, Ginestet Ch et al (2004) A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: Clinical and dosimetric factors analysis. Radiother Oncol 71:175-181
21. Wang Sh, Liao Z, Wei X et al (2006) Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis in patients with non small cell lung cancer treated with concurrent chemotherapy and 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 66:1399-1407
22. Miller K, Shafman T, Marks L et al (2004) A practical approach to pulmonary risk assessment in the radiotherapy of lung cancer. Semin Radiat Oncol 14:298-307
23. Yorke ED, Jackson A, Rosenzweig KE et al (2004) Correlation of dosimetric factors and radiation pneumonitis incidence for non small cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 60:S240
24. Seppenwoolde Y, Lebesque JV, De Jaeger K et al (2003) Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys 55:724-735
25. Schallenkamp JM, Miller RC, Brinkmann DH et al (2007) Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates. Int J Radiat Oncol Biol Phys 67:410-416
26. Belderbos J, De Jaeger K, Heemsbergen W et al (2003) First results of a phase I/II dose escalation trial in non-small cell lung cancer using 3D conformal radiotherapy. Radiother Oncol 66: 119-126
27. Bradley J, Graham MV, Winter K et al (2005) Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using 3D conformal radiotherapy in patients with inoperable nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys 61:318-328
28. Kong F, Hayman J, Griffith K et al (2006) Final toxicity results of a radiation-dose escalation study in patients with non-small cell lung cancer: Predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 65:1075-1086
29. Socinski M, Morris D, Halle J et al (2004) Induction and concurrent chemotherapy with highdose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: A dose-escalation phase I trial. J Clin Oncol 22:4341-4350
30. Marks L, Munley M, Bentel G et al (1997) Physical and biological predictors of changes in whole lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys 39:563-570
31. Fu XL, Huang H, Bentel G et al (2001) Predicting the risk of symptomatic radiation induced lung injury using the physical and biologic parameters V30 Gy and TGF-β. Int J Radiat Oncol Biol Phys 50:899-908
32. De Jaeger K, Seppenwoolde Y, Harm H et al (2004) Significance of plasma transforming growth factor-β levels in radiotherapy for nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 58:1378-1387
33. Rancati T, Ceresoli GL, Gagliardi G (2003) Factors predicting radiation pneumonitis in lung cancer patients: A retrospective study. Radiother Oncol 67:89-94
34. Gopal R (2005) Pulmonary toxicity associated with the treatment of non-small-cell lung cancer and the effects of cytoprotective strategies. Semin Oncol 32[Suppl 3]:S55-59
35. Komaki R, Soo Lee J, Milas L et al (2004) Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: Report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58:1369-1377
36. Werner-Wasik M, Scott C, Movsas B et al (2003) Amifostine as mucosal protectant in patients with locally advanced non small cell lung cancer receiving intensive chemotherapy and thoracic radiotherapy: Results of the RTOG 98-01 study. Int J Radiat Oncol Biol Phys 57:S216
37. Tsujino K, Hirota S, Kotani Y et al (2006) Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation. Int J Radiat Oncol Biol Phys 64:1100-1105
38. Saunders M, Dische S, Barrett A et al (1997) Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: A randomized multicentre trial. CHART Steering Committee. Lancet 350:161-165
39. Sekine I, Sumi M, Ito Y et al (2006) Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients. Radiother Oncol 80:93-97
40. Ward WF, Lin PJ, Wong PS et al (1993) Radiation pneumonitis in rats and its modification by the angiotensin-converting enzyme inhibitor captopril evaluated by high resolution computed tomography. Radiat Res 135:81-87
41. Molteni A, Moulder JE, Cohen EF et al (2000) Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Oncol Biol Phys 76: 523-532
42. Ozturk B, Egehan I, Atavci S et al (2004) Pentoxifylline in prevention of radioinduced lung toxicity in patients with breast and lung cancer: A double-blind randomized trial. Int J Radiat Oncol Biol Phys 58:213-219